According to Steven P. Treon, MD, PhD, mutations in MYD88 and CXCR4 can effectively be used to tailor treatment for patients with Waldenström’s macroglobulinemia (WM).
“Linking biological data to clinical data is beginning to identify clinically distinct subgroups with different disease characteristics and outcomes,” said Treon, director of the Bing Center for Waldenström’s Macroglobulinemia and physician at Dana-Farber Cancer Institute, during a “How I Treat”session at the inaugural ASH Meeting on Hematologic Malignancies. “Mutational testing identifies patients with actionable mutations that may respond to specific therapy. Additionally, poor prognostic genetic markers have an additive effect. We need to consider novel approaches for these patients within the context of clinical trials.